Nubilaria ACTide to attend BIO Digital International Convention
With collaboration being more important now than ever before, Nubilaria ACTide will attend BIO Digital to be a part of
Read more
Press Releases
Watlow Launches Batch Processing for Thermal Data Controller and Data Logger
Watlow, an industry pioneer in the design and manufacture of complete thermal systems, has recently launched a batch processing feature
Read more
ACTide EDC (Electronic Data Capture) System against COVID-19
Nubilaria, a forward thinking clinical data management company, has released an important announcement for Researchers and Health Professionals in Europe
Read more
FDA clears Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for GIST
Deciphera Pharmaceuticals, Inc. has revealed that QINLOCK™ (ripretinib) was formally authorised by the U.S. Food and Drug Administration (FDA) for
Read more
Metrohm unveils new modular 2060 Process Analyzer
The new 2060 Process Analyzer by Metrohm Process Analytics offers customized online monitoring of critical chemical parameters in industrial processes
Read more
Join Nubilaria ACTide at the OCT 2020 virtual conference
Nubilaria ACTide will attend the Outsourcing in Clinical Trials 2020 virtual conference hosted by Arena International. The unique one-day global
Read more
Shionogi receives EC approval for new antibiotic FETCROJA® (cefiderocol)
Japanese research-driven pharmaceutical company Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. announced on April 28 that the
Read more
ARTES joins fight against COVID-19 with VLP vaccine platforms
ARTES Biotechnology, a Germany-based biotechnology company specialising in process development for recombinant vaccines, has commenced the development of SARS-CoV-2 vaccine
Read more
Vaxart shows positive pre-clinical data for oral COVID-19 vaccine
Vaxart, a clinical-stage biotechnology organisation developing oral recombinant vaccines delivered via tablet rather than an injection, reported on April 21
Read more
Intermediate analysis of Moderna’s Phase I Zika Vaccine (mRNA-1893)
The first intermediate analysis of the Phase I Zika vaccine candidate sample (mRNA-1893) reveals that the dosage levels of 10
Read more